FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 160 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $305,000 | +33.8% | 50,000 | -50.0% | 0.00% | 0.0% |
| Q1 2020 | $228,000 | -0.9% | 100,000 | +100.0% | 0.00% | 0.0% |
| Q4 2019 | $230,000 | -61.9% | 50,000 | +11.1% | 0.00% | -50.0% |
| Q1 2019 | $603,000 | +150.2% | 45,000 | +221.4% | 0.00% | +100.0% |
| Q1 2018 | $241,000 | -21.5% | 14,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $307,000 | -58.3% | 14,000 | -22.2% | 0.00% | -66.7% |
| Q3 2017 | $736,000 | +62.8% | 18,000 | +20.0% | 0.00% | +50.0% |
| Q2 2017 | $452,000 | +4.1% | 15,000 | +25.0% | 0.00% | 0.0% |
| Q1 2017 | $434,000 | -42.3% | 12,000 | -20.0% | 0.00% | -50.0% |
| Q4 2016 | $752,000 | -4.4% | 15,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $787,000 | +32.3% | 15,000 | +4.2% | 0.00% | +33.3% |
| Q2 2016 | $595,000 | +1.7% | 14,400 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $585,000 | -34.6% | 14,400 | -33.2% | 0.00% | -25.0% |
| Q4 2015 | $894,000 | – | 21,550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |